1 active not recruiting, 1 completed, 1 not yet recruiting, 1 recruiting. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 1, Completed 1, Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Orygen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lisdexamfetamine For the Treatment of Conduct Disorder in Children Lidexamfetamine - Conduct Disorder | Phase 2 | Not yet recruiting | Orygen | 30 | 2027-02-01 | 2026-11-06 |
| Hybrid Type 2 Implementation-Effectiveness Trial of a Third Wave Virtual Reality Treatment for Youth Depression/Anxiety Third wave VR therapy - Depression Anxiety Disorder | Phase 2 | Active not recruiting | Orygen | 75 | 2025-04-01 | 2026-09-14 |
| Guanfacine Extended-release for Adolescents With Cannabis Use Guanfacine Extended Release Oral Tablet, Residential withdrawal, Engagement with alcohol and other drug services - Cannabis Use Disorder | Phase 2 | Recruiting | Orygen | 100 | 2023-07-27 | 2025-07-31 |
| Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome. omega-3 PUFAs, Standard care, placebo - 22q11 Deletion Syndrome | Phase 2 / Phase 3 | Unknown | Bambino Gesù Hospital and Research Institute | 80 | 2014-06-01 | 2014-02-25 |
| Promotion of Self-help Strategies for Depression Mood Memo emails - Depressive Disorder, Depression | Phase 1 / Phase 2 | Completed | Orygen | 1736 | 2011-11-01 | 2013-12-11 |
Depression (2) · 22q11 Deletion Syndrome (1) · Aggression (1) · Anxiety Disorders (1) · Conduct Disorder (1) · Depressive Disorder (1) · Psychotic Disorders (1)
Ethanol (1) · Fish Oils (1) · Guanfacine (1) · Standard of Care (1)
Australia (3) · Holy See (1)
Alexandre A Guerin, PhD (1) · Andrew J Mackinnon, PhD (1) · Anthony F Jorm, PhD, DSc (1) · Marco Armando, MD, PhD (1)